• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于多模式抗血管治疗的纳米颗粒:双重药物释放、光热和光动力疗法。

Nanoparticles for multimodal antivascular therapeutics: Dual drug release, photothermal and photodynamic therapy.

机构信息

Dpto. Química en Ciencias Farmacéuticas (Unidad Docente de Química Inorgánica y Bioinorgánica), Facultad de Farmacia, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid 28040, Spain; Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Spain.

Dpto. Química en Ciencias Farmacéuticas (Unidad Docente de Química Inorgánica y Bioinorgánica), Facultad de Farmacia, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid 28040, Spain; Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Spain.

出版信息

Acta Biomater. 2020 Jan 1;101:459-468. doi: 10.1016/j.actbio.2019.11.004. Epub 2019 Nov 6.

DOI:10.1016/j.actbio.2019.11.004
PMID:31706040
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7616912/
Abstract

The poor delivery of nanoparticles to target cancer cells hinders their success in the clinical setting. In this work, an alternative target readily available for circulating nanoparticles has been selected to eliminate the need for nanoparticle penetration in the tissue: the tumor blood vessels. A tumor endothelium-targeted nanoparticle (employing an RGD-containing peptide) capable of co-delivering two anti-vascular drugs (one anti-angiogenic drug and one vascular disruption agent) is here presented. Furthermore, the nanodevice presents two additional anti-vascular capabilities upon activation by Near-Infrared light: provoking local hyperthermia (by gold nanorods in the system) and generating toxic reactive oxygen species (by the presence of a photosensitizer). RGD-targeting is shown to increase uptake by HUVEC cells, and while the nanoparticles are shown not to be toxic for these cells, upon Near-Infrared irradiation their almost complete killing is achieved. The combination of all four therapeutic modalities is then evaluated in an ex ovo fibrosarcoma xenograft model, which shows a significant reduction in the number of blood vessels irrigating the xenografts when the nanoparticles are present, as well as the destruction of the existing blood vessels upon irradiation. These results suggest that the combination of different anti-vascular therapeutic strategies in a single nanocarrier appears promising and should be further explored in the future. STATEMENT OF SIGNIFICANCE MVR2019: The combination of antivascular drugs with different mechanisms of action (such as antiangiogenic drugs and vascular disruption agents) has been recently proposed as a promising approach to maximize the therapeutic potential of anti-vascular therapeutics. Given the capacity of nanoparticles to co-deliver different drugs in optimizable ratios, nanomedicine appears to have a huge potential for the development of this kind of multimodal antivascular. To showcase this, an multimodal anti-vascular nanodevice for cancer therapy is here presented. This tumor endothelium-targeted nanosystem is capable of co-delivering two anti-vascular drugs (anti-angiogenic and vascular disruption agent) while also providing two additional therapeutic modalities that can be activated by Near-Infrared light: provoking local hyperthermia (photothermal therapy) and generating toxic reactive oxygen species (photodynamic therapy).

摘要

纳米颗粒向靶癌细胞的递送不良阻碍了它们在临床环境中的成功。在这项工作中,选择了一种可供循环纳米颗粒使用的替代靶标,以消除纳米颗粒在组织中穿透的需要:肿瘤血管。本文提出了一种肿瘤内皮靶向纳米颗粒(采用含有 RGD 的肽),能够共递两种抗血管药物(一种抗血管生成药物和一种血管破坏剂)。此外,该纳米器件在近红外光激活后具有另外两种抗血管能力:通过系统中的金纳米棒引发局部热疗(hyperthermia)和通过存在光敏剂产生有毒的活性氧物质。RGD 靶向被证明可以增加 HUVEC 细胞的摄取,虽然纳米颗粒对这些细胞没有毒性,但近红外照射后几乎可以完全杀死它们。然后在鸡胚纤维肉瘤异种移植模型中评估了所有四种治疗模式的组合,结果表明,当存在纳米颗粒时,灌溉异种移植物的血管数量显著减少,并且照射后现有的血管被破坏。这些结果表明,将不同的抗血管治疗策略组合在单个纳米载体中具有很大的潜力,应该在未来进一步探索。

相似文献

1
Nanoparticles for multimodal antivascular therapeutics: Dual drug release, photothermal and photodynamic therapy.用于多模式抗血管治疗的纳米颗粒:双重药物释放、光热和光动力疗法。
Acta Biomater. 2020 Jan 1;101:459-468. doi: 10.1016/j.actbio.2019.11.004. Epub 2019 Nov 6.
2
Actively targeting D-α-tocopheryl polyethylene glycol 1000 succinate-poly(lactic acid) nanoparticles as vesicles for chemo-photodynamic combination therapy of doxorubicin-resistant breast cancer.主动靶向D-α-生育酚聚乙二醇1000琥珀酸酯-聚乳酸纳米粒作为载体用于多柔比星耐药乳腺癌的化学-光动力联合治疗
Nanoscale. 2016 Feb 7;8(5):3100-18. doi: 10.1039/c5nr07724a.
3
Tumor-Targeting HO-Responsive Photosensitizing Nanoparticles with Antiangiogenic and Immunogenic Activities for Maximizing Anticancer Efficacy of Phototherapy.具有抗血管生成和免疫原性活性的肿瘤靶向 HO 响应型光敏纳米颗粒,最大限度提高光疗的抗癌疗效。
ACS Appl Bio Mater. 2021 May 17;4(5):4450-4461. doi: 10.1021/acsabm.1c00210. Epub 2021 May 3.
4
Near-infrared light triggered drug delivery system for higher efficacy of combined chemo-photothermal treatment.用于提高化疗-光热联合治疗疗效的近红外光触发药物递送系统。
Acta Biomater. 2017 Mar 15;51:374-392. doi: 10.1016/j.actbio.2016.12.004. Epub 2017 Jan 11.
5
Folate-mediated and pH-responsive chidamide-bound micelles encapsulating photosensitizers for tumor-targeting photodynamic therapy.叶酸介导和 pH 响应的西达本胺结合胶束包载光敏剂用于肿瘤靶向光动力治疗。
Int J Nanomedicine. 2019 Jul 22;14:5527-5540. doi: 10.2147/IJN.S208649. eCollection 2019.
6
Folate-receptor-targeted laser-activable poly(lactide--glycolic acid) nanoparticles loaded with paclitaxel/indocyanine green for photoacoustic/ultrasound imaging and chemo/photothermal therapy.载紫杉醇/吲哚菁绿的叶酸受体靶向激光激活聚乳酸-乙醇酸纳米粒用于光声/超声成像及化疗/光热治疗。
Int J Nanomedicine. 2018 Sep 6;13:5139-5158. doi: 10.2147/IJN.S167043. eCollection 2018.
7
Tumor vascular-targeted co-delivery of anti-angiogenesis and chemotherapeutic agents by mesoporous silica nanoparticle-based drug delivery system for synergetic therapy of tumor.基于介孔二氧化硅纳米颗粒的药物递送系统实现肿瘤血管靶向共递送抗血管生成药物和化疗药物用于肿瘤协同治疗
Int J Nanomedicine. 2015 Dec 29;11:93-105. doi: 10.2147/IJN.S81156. eCollection 2016.
8
Polydopamine-coated gold nanostar for combined antitumor and antiangiogenic therapy in multidrug-resistant breast cancer.聚多巴胺包覆的金纳米星用于多药耐药乳腺癌的联合抗肿瘤和抗血管生成治疗。
Nanotheranostics. 2019 Jun 6;3(3):266-283. doi: 10.7150/ntno.36842. eCollection 2019.
9
A light-controllable specific drug delivery nanoplatform for targeted bimodal imaging-guided photothermal/chemo synergistic cancer therapy.一种光控的靶向双模态成像引导光热/化疗协同治疗的特异药物递送纳米平台。
Acta Biomater. 2018 Oct 15;80:308-326. doi: 10.1016/j.actbio.2018.09.024. Epub 2018 Sep 19.
10
Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.Delta-like 配体 4 靶向纳米医学用于抗血管生成癌症治疗。
Biomaterials. 2015 Feb;42:161-71. doi: 10.1016/j.biomaterials.2014.11.039. Epub 2014 Dec 16.

引用本文的文献

1
Advances in nanocarrier-mediated cancer therapy: Progress in immunotherapy, chemotherapy, and radiotherapy.纳米载体介导的癌症治疗进展:免疫疗法、化学疗法和放射疗法的进展
Chin Med J (Engl). 2025 Aug 20;138(16):1927-1944. doi: 10.1097/CM9.0000000000003703. Epub 2025 Jun 23.
2
Doxycycline-Induced Apoptosis in S2-Infected HMC3 Cells via Calreticulin Suppression and Activation of the IRE1/Caspase-3 Signaling Pathway.强力霉素通过抑制钙网蛋白和激活IRE1/半胱天冬酶-3信号通路诱导S2感染的HMC3细胞凋亡。
Infect Drug Resist. 2025 Apr 23;18:2005-2020. doi: 10.2147/IDR.S507193. eCollection 2025.
3
Nanocarriers for targeted drug delivery in the vascular system: focus on endothelium.

本文引用的文献

1
pH-activatable polymeric nanodrugs enhanced tumor chemo/antiangiogenic combination therapy through improving targeting drug release.pH 激活型聚合物纳米药物通过改善靶向药物释放增强肿瘤化疗/抗血管生成联合治疗。
J Colloid Interface Sci. 2019 Feb 15;536:135-148. doi: 10.1016/j.jcis.2018.10.039. Epub 2018 Oct 16.
2
Doxycycline, an Inhibitor of Mitochondrial Biogenesis, Effectively Reduces Cancer Stem Cells (CSCs) in Early Breast Cancer Patients: A Clinical Pilot Study.强力霉素,一种线粒体生物发生的抑制剂,可有效减少早期乳腺癌患者的癌症干细胞(CSCs):一项临床试点研究。
Front Oncol. 2018 Oct 12;8:452. doi: 10.3389/fonc.2018.00452. eCollection 2018.
3
纳米载体在血管系统中靶向药物递送的应用:聚焦于内皮细胞。
J Nanobiotechnology. 2024 Oct 12;22(1):620. doi: 10.1186/s12951-024-02892-9.
4
Bioproduced Nanoparticles Deliver Multiple Cargoes via Targeted Tumor Therapy In Vivo.生物合成纳米颗粒通过靶向肿瘤疗法在体内递送多种药物。
ACS Omega. 2024 Jul 23;9(31):33789-33804. doi: 10.1021/acsomega.4c03277. eCollection 2024 Aug 6.
5
Unraveling Endothelial Cell Migration: Insights into Fundamental Forces, Inflammation, Biomaterial Applications, and Tissue Regeneration Strategies.解析内皮细胞迁移:对基本作用力、炎症、生物材料应用及组织再生策略的见解
ACS Appl Bio Mater. 2024 Apr 15;7(4):2054-2069. doi: 10.1021/acsabm.3c01227. Epub 2024 Mar 23.
6
Quantum Dot-based Bio-conjugates as an Emerging Bioimaging Tool for Cancer Theranostic- A Review.基于量子点的生物缀合物作为癌症治疗诊断的新兴生物成像工具——综述
Curr Drug Targets. 2024;25(4):241-260. doi: 10.2174/0113894501283669240123105250.
7
Nanomedical research and development in Spain: improving the treatment of diseases from the nanoscale.西班牙的纳米医学研发:从纳米尺度改善疾病治疗
Front Bioeng Biotechnol. 2023 Jul 21;11:1191327. doi: 10.3389/fbioe.2023.1191327. eCollection 2023.
8
Smart Nanomaterials in Cancer Theranostics: Challenges and Opportunities.癌症诊疗中的智能纳米材料:挑战与机遇
ACS Omega. 2023 Apr 10;8(16):14290-14320. doi: 10.1021/acsomega.2c07840. eCollection 2023 Apr 25.
9
Advances in nanomaterial-based targeted drug delivery systems.基于纳米材料的靶向药物递送系统的进展。
Front Bioeng Biotechnol. 2023 Apr 13;11:1177151. doi: 10.3389/fbioe.2023.1177151. eCollection 2023.
10
Nanomaterial-Based Antivascular Therapy in the Multimodal Treatment of Cancer.基于纳米材料的抗血管生成疗法在癌症多模态治疗中的应用
Pharmaceutics. 2023 Apr 11;15(4):1207. doi: 10.3390/pharmaceutics15041207.
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
4
Chick chorioallantoic membrane assay as an in vivo model to study the effect of nanoparticle-based anticancer drugs in ovarian cancer.鸡胚尿囊膜分析作为一种体内模型,用于研究基于纳米粒子的抗癌药物在卵巢癌中的作用。
Sci Rep. 2018 Jun 4;8(1):8524. doi: 10.1038/s41598-018-25573-8.
5
Analyses of repeated failures in cancer therapy for solid tumors: poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs.实体瘤癌症治疗中反复失败的分析:肿瘤选择性药物递送不佳、治疗效果低以及成本难以持续。
Clin Transl Med. 2018 Mar 1;7(1):11. doi: 10.1186/s40169-018-0185-6.
6
Recent advances in anti-angiogenic nanomedicines for cancer therapy.近年来用于癌症治疗的抗血管生成纳米药物的进展。
Nanoscale. 2018 Mar 28;10(12):5393-5423. doi: 10.1039/c7nr09612g. Epub 2018 Mar 12.
7
Mesoporous Silica Nanoparticles for Drug Delivery: Current Insights.介孔二氧化硅纳米颗粒用于药物传递:当前的见解。
Molecules. 2017 Dec 25;23(1):47. doi: 10.3390/molecules23010047.
8
Nanomedicine 2.0.纳米医学 2.0.
Acc Chem Res. 2017 Mar 21;50(3):627-632. doi: 10.1021/acs.accounts.6b00629.
9
Targeting hypoxic cancer stem cells (CSCs) with Doxycycline: Implications for optimizing anti-angiogenic therapy.用强力霉素靶向缺氧癌干细胞:对优化抗血管生成治疗的意义
Oncotarget. 2017 Jun 12;8(34):56126-56142. doi: 10.18632/oncotarget.18445. eCollection 2017 Aug 22.
10
Realizing the Potential of Vascular Targeted Therapy: The Rationale for Combining Vascular Disrupting Agents and Anti-Angiogenic Agents to Treat Cancer.实现血管靶向治疗的潜力:联合血管破坏剂和抗血管生成剂治疗癌症的基本原理。
Cancer Invest. 2017 Sep 14;35(8):519-534. doi: 10.1080/07357907.2017.1364745. Epub 2017 Sep 5.